KF BU - Medical Representative

KF PT. Kalbe Farma Tbk.; Tegal; On-site; IDR 78,120,000 - 122,760,000; Full time

Job summary

KF PT. Kalbe Farma Tbk. membuka kesempatan bagi tenaga penjualan yang bertugas membangun dan memelihara hubungan dengan klien untuk mencapai target penjualan perusahaan.

Kandidat diharapkan mampu melaksanakan rencana aksi penjualan bulanan dan triwulanan yang telah ditetapkan atasan, dengan fokus pada kunjungan pelanggan, pengeluaran, dan target penjualan per outlet. Peran ini menuntut kemampuan komunikasi yang kuat, negosiasi, serta orientasi pada hasil dan pelanggan.

Qualifications

• Mengembangkan dan mempertahankan hubungan dengan klien.

Responsibilities

• Develop and maintain client relationships.
• Execute sales plan of actions as deployed from superior on monthly and quarterly basis (include plan of customer visit, expenses, sales target per outlet/customer, dll).
• Mengembangkan dan mempertahankan hubungan dengan klien.
• Melaksanakan rencana aksi penjualan yang diberikan oleh atasan secara bulanan dan triwulanan (termasuk rencana kunjungan pelanggan, pengeluaran, target penjualan per outlet/pelanggan, dll).

Job description

Job Description

• Develop and maintain client relationships.
• Execute sales plan of actions as deployed from superior on monthly and quarterly basis (include plan of customer visit, expenses, sales target per outlet/customer, etc).
• Mengembangkan dan mempertahankan hubungan dengan klien.
• Melaksanakan rencana aksi penjualan yang diberikan oleh atasan secara bulanan dan triwulanan (termasuk rencana kunjungan pelanggan, pengeluaran, target penjualan per outlet/pelanggan, dll).

Founded in 1966, Kalbe Farma (Kalbe) is the largest publicly-listed pharmaceutical company in Southeast Asia. As of end 2023, Kalbe’s extensive healthcare ecosystem encompasses a network of 47 companies, including subsidiaries, joint ventures, and associates, all driven by a dedicated workforce of 16,795 employees. Guided by a vision to become the country’s best global healthcare company, Kalbe offers a comprehensive healthcare solution through its four key business divisions: prescription pharmaceuticals, consumer health, nutrition, and distribution & logistics. Within these divisions, Kalbe manages a diverse portfolio reinforced by a robust distribution network that serves over one million outlets across Indonesia’s vast archipelago. On the international stage, Kalbe has established a strong presence in ASEAN countries, as well as regions spanning East and South Asia, the Middle East, and Africa. Kalbe’s business ventures are supported by best in- class research and development capabilities, developed through strategic alliances with many international partners. The Company is deeply involved in cutting‑edge areas such as drug delivery systems, cancer treatment, stem cell research, and biotechnology.

Company: KF PT. Kalbe Farma Tbk. Founded in 1966, Kalbe Farma (Kalbe) is the largest publicly‑listed pharmaceutical company in Southeast Asia. As of end 2023, Kalbe’s extensive healthcare ecosystem encompasses a network of 47 companies, including subsidiaries, joint ventures, and associates, all driven by a dedicated workforce of 16,795 employees. Guided by a vision to become the country’s best global healthcare company, Kalbe offers a comprehensive healthcare solution through its four key business divisions: prescription pharmaceuticals, consumer health, nutrition, and distribution & logistics. Within these divisions, Kalbe manages a diverse portfolio reinforced by a robust distribution network that serves over one million outlets across Indonesia’s vast archipelago. On the international stage, Kalbe has established a strong presence in ASEAN countries, as also regions spanning East and South Asia, the Middle East, and Africa. Kalbe’s business ventures are supported by bestin- class research and development capabilities, developed through strategic alliances with many international partners. The Company is deeply involved in cutting‑edge areas such as drug delivery systems, cancer treatment, stem cell research, and biotechnology.